EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management

Jian Liu, Xinyan Wu, Ting Yin, Feining Huang, Manqi Kong, Yu Yang, Zinan Liu, Jiabin Yu, Tianpeng Zhang

MedComm · 2026-07 · 7 (7)

DOI: 10.1002/mco2.70837 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 30.06.2026. Verfasst von Jian Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences Guangzhou University of Chinese Medicine Guangzhou China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 312 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is a common neurological disorder with a substantial global burden. Despite major advances in diagnosis and therapy, nearly one‐third of patients remain resistant to antiseizure medications, highlighting persistent gaps in understanding epileptogenesis and disease progression. Here, we review epidemiological evidence, time‐dependent seizure patterns, and pathogenic mechanisms that contribute to epilepsy. We discuss how genetic variants, ion‐channel dysfunction, altered synaptic transmission, neuroinflammation, metabolic and mitochondrial stress, structural remodeling, network reorganization, and epigenetic regulation converge to destabilize neural circuits. These processes interact across disease stages and promote persistent hyperexcitability. We further summarize how mechanistic advances are reshaping clinical management, including precision diagnostics, pharmacotherapy, surgery, neuromodulation, dietary and lifestyle intervention, chronotherapy, biomarker‐guided stratification, and emerging disease‐modifying approaches such as immunotherapy, pathway‐targeted treatment, RNA‐based therapeutics, and gene‐directed strategies. Data‐driven tools for seizure detection and forecasting are also discussed as complementary approaches for individualized care. Overall, current evidence supports a shift from empirical seizure suppression toward mechanism‐guided and individualized care. Future progress will require closer integration of molecular discovery, validated biomarkers, and real‐world implementation to achieve earlier, more equitable, and potentially disease‐modifying treatment.

Schlagwörter

Stichwörter der Autor:innen

clinical managementepidemiologyepilepsymechanism

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences Guangzhou University of Chinese Medicine Guangzhou China.
  • Key Laboratory of Chinese Medicinal Resource from Lingnan (School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine) Ministry of Education Guangzhou China.
  • Institute of Molecular Rhythm and Metabolism Guangzhou University of Chinese Medicine Guangzhou China.

Zitieren

APA

Liu, J., Wu, X., Yin, T., Huang, F., Kong, M., Yang, Y., Liu, Z., Yu, J., & Zhang, T. (2026). Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management. MedComm, 7(7). https://doi.org/10.1002/mco2.70837

Vancouver

Liu J, Wu X, Yin T, Huang F, Kong M, Yang Y, et al. Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management. MedComm. 2026;7(7). doi:10.1002/mco2.70837

BibTeX
@article{Liu2026,
  author = {Liu, Jian and Wu, Xinyan and Yin, Ting and Huang, Feining and Kong, Manqi and Yang, Yu and Liu, Zinan and Yu, Jiabin and Zhang, Tianpeng},
  title = {Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {7},
  doi = {10.1002/mco2.70837}
}
Kostenlos starten →